CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand. This...
Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications
BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology company....
Doppel Enters Japan, Marking Next Phase of Global Expansion
Social engineering defense leader surpasses 250 customers, launches new email security offerings, and adds industry veterans to executive team SAN FRANCISCO, June 16, 2026 /PRNewswire/ -- Doppel, the AI-native Social Engineering Defense (SED)...
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory...
MDP Enters OLIVE YOUNG
MDP launched four key SKUs at OLIVE YOUNG Pasadena, which opened on May 29. Additional rollout planned for the upcoming OLIVE YOUNG Century City location in mid-June. SEOUL, South Korea, June 9, 2026 /PRNewswire/ -- MDP, MEDIPEEL's U.S. market...
Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel
SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China
SHANGHAI, June 8, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Fiddler's Green Amphitheatre Enters New Era of Connectivity with Boldyn Networks' 5G Infrastructure
AEG Presents venue in Denver now live with next-generation wireless network for seamless fan connectivity DENVER, June 4, 2026 /PRNewswire/ -- Boldyn Networks (Boldyn), a global leader in shared network infrastructure, today announced the successful...
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New...
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases Civorebrutinib adds pipeline-in-a-product potential across multiple...